SUPERNUS PHARMACEUTICALS, INC.
SUPNDrugs in Pipeline
22
Phase 3 Programs
14
Upcoming Catalysts
5
Next Catalyst
Aug 4, 2026
15dMarket Overview
Stock performance and key metrics
5 upcoming, 0 past
How SUPN's past catalysts played out
SAGE-547 60 μg/kg/h
Postpartum Depression
400mg SPN-812
ADHD
SPN-810 (18 mg)
Attention Deficit Hyperactivity Disorder (ADHD)
Brexanolone
Tinnitus
100mg SPN-812
Attention-Deficit/Hyperactivity Disorder (ADHD)
SAGE-547
Postpartum Depression
apomorphine infusion
Idiopathic Parkinson's Disease
SPN-810 (36 mg)
Attention Deficit Hyperactivity Disorder (ADHD)
SPN-812
Attention-Deficit/Hyperactivity Disorder
MYOBLOC
Sialorrhea
200mg SPN-812
ADHD
2400mg SPN-804
Epilepsies, Partial
Oxcarbazepine XR
Partial Epilepsy
SAGE-547 90 μg/kg/h
Postpartum Depression
SPN-821 2400 mg
Major Depressive Disorder (MDD)
SAGE-718
Alzheimer Disease
Molindone
Impulsive Aggression Comorbid With ADHD in Children
BIS-001ER
Focal Impaired Awareness Seizures
SPN-817
Focal Onset Seizures
IR Viloxazine
Attention-Deficit/Hyperactivity Disorder (ADHD)
SPN-810
Attention Deficit Disorder With Hyperactivity
TPM XR
Epilepsy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SAGE-547 60 μg/kg/h | Phase 3 | Postpartum Depression | - | - |
400mg SPN-812 | Phase 3 | ADHD | - | - |
SPN-810 (18 mg) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - | - |
Brexanolone | Phase 3 | Tinnitus | - | - |
100mg SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - | - |
SAGE-547 | Phase 3 | Postpartum Depression | - | - |
apomorphine infusion | Phase 3 | Idiopathic Parkinson's Disease | - | - |
SPN-810 (36 mg) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - | - |
SPN-812 | Phase 3 | Attention-Deficit/Hyperactivity Disorder | - | - |
MYOBLOC | Phase 3 | Sialorrhea | - | - |
200mg SPN-812 | Phase 3 | ADHD | - | - |
2400mg SPN-804 | Phase 3 | Epilepsies, Partial | - | - |
Oxcarbazepine XR | Phase 3 | Partial Epilepsy | - | - |
SAGE-547 90 μg/kg/h | Phase 3 | Postpartum Depression | - | - |
SPN-821 2400 mg | Phase 2 | Major Depressive Disorder (MDD) | - | - |
SAGE-718 | Phase 2 | Alzheimer Disease | - | - |
Molindone | Phase 2 | Impulsive Aggression Comorbid With ADHD in Children | - | - |
BIS-001ER | Phase 2 | Focal Impaired Awareness Seizures | - | - |
SPN-817 | Phase 2 | Focal Onset Seizures | - | - |
IR Viloxazine | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | - | - |
SPN-810 | Phase 2 | Attention Deficit Disorder With Hyperactivity | - | - |
TPM XR | Phase 2 | Epilepsy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SUPERNUS PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 22 drug candidates in SUPERNUS PHARMACEUTICALS, INC.'s (SUPN) pipeline across Phase 3, Phase 2. Its lead program is SAGE-547 60 μg/kg/h (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SUPERNUS PHARMACEUTICALS, INC.'s next FDA catalyst?→
SUPERNUS PHARMACEUTICALS, INC.'s (SUPN) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SUPN biotech catalysts?→
Add SUPN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SUPERNUS PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.